Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Advanced Drug Delivery Reviews

• Publication date

  2009-05-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.addr.2008.10.005PMID 19135108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Pharmacokinetics and Administration of Established Platinum Drugs

  2012cited by this paper
• Clinical Perspectives on Platinum Resistance

  2012cited by this paper
• Pharmacotherapy for Oesophagogastric Cancer

  2012cited by this paper
• Genomic profiling of 766 cancer‐related genes in archived esophageal normal and carcinoma tissues

  2008cited by this paper
• Correlation between Loss of Bcl-XL Expression and Improved Prognosis in Advanced Esophageal Cancer Treated by Preoperative Chemoradiotherapy

  2008cited by this paper
• Trends in esophageal cancer incidence by histology, United States, 1998–2003

  2008cited by this paper
• Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute.

  2008cited by this paper
• Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomas.

  2008cited by this paper
• Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

  2008cited by this paper
• Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.

  2008cited by this paper
• Proteomic identification of malignant transformation‐related proteins in esophageal squamous cell carcinoma

  2008cited by this paper
• Trends in incidence of esophageal and gastric cardia cancer in high-risk areas in China

  2008cited by this paper
• Fruit and vegetable consumption and squamous cell carcinoma of the esophagus in Japan: The JPHC study

  2008cited by this paper
• Plasma DNA is more reliable than carcinoembryonic antigen for diagnosis of recurrent esophageal cancer.

  2008cited by this paper
• Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status.

  2008cited by this paper
• Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy

  2008cited by this paper
• Esophageal cancer: epidemiology, pathogenesis and prevention

  2008cited by this paper
• Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  2008cited by this paper
• Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma.

  2008cited by this paper
• Alterations in Barrett's‐related adenocarcinomas: A proteomic approach

  2008cited by this paper
• Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients.

  2008cited by this paper
• Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.

  2008cited by this paper
• Whole genome-wide association study using affymetrix SNP chip: a two-stage sequential selection method to identify genes that increase the risk of developing complex diseases.

  2008cited by this paper
• Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer.

  2008cited by this paper
• Cancer Pharmacogenomics: DNA Genotyping and Gene Expression Profiling to Identify Molecular Determinants of Chemosensitivity

  2008cited by this paper
• Is It Time for a New TNM Classification in Esophageal Carcinoma?

  2008cited by this paper
• Single Nucleotide Polymorphisms in Obesity-Related Genes and the Risk of Esophageal Cancers

  2008cited by this paper
• Pharmacogenetic relevance of MTHFR polymorphisms.

  2008cited by this paper
• The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients.

  2008cited by this paper
• Association of Matrix Metalloproteinases-9 Gene Polymorphisms with Genetic Susceptibility to Esophageal Squamous Cell Carcinoma

  2008cited by this paper
• From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma

  2008cited by this paper
• A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma

  2008cited by this paper
• Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma

  2008cited by this paper
• Cancer of the esophagus and stomach.

  2008cited by this paper
• Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001.

  2008cited by this paper
• Circulating micrometastases of esophageal cancer detected by carcinoembryonic antigen mRNA reverse transcriptase-polymerase chain reaction: clinical implications.

  2008cited by this paper
• VEGF G-1154A is Predictive of Severe Acute Toxicities during Chemoradiotherapy for Esophageal Squamous Cell Carcinoma in Japanese Patients

  2008cited by this paper
• High throughput techniques for characterizing the expression profile of Barrett's esophagus.

  2008cited by this paper
• Improved local control by surgery and paclitaxel‐based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non‐randomized study

  2008cited by this paper
• Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.

  2008cited by this paper
• Replication of a genome‐wide case–control study of esophageal squamous cell carcinoma

  2008cited by this paper
• Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome.

  2008cited by this paper
• Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer.

  2007cited by this paper
• Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer: Phase II Results of Preliminary Pharmacologic and Molecular Efforts to Mitigate Toxicity and Predict Outcomes: North Central Cancer Treatment Group (N0044)

  2007cited by this paper
• Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma

  2007cited by this paper
• A cell cycle automaton model for probing circadian patterns of anticancer drug delivery.

  2007cited by this paper
• Therapeutic drug monitoring of cancer chemotherapy

  2007cited by this paper
• Glutathione S-transferase P1 genotypes, genetic susceptibility and outcome of therapy in thai childhood acute lymphoblastic leukemia.

  2007cited by this paper
• A Systematic Review of Limited Sampling Strategies for Platinum Agents Used in Cancer Chemotherapy

  2007cited by this paper
• Assessment of Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma Using TNM Classification Score and Molecular Biological Classification

  2007cited by this paper
• ABCG2 Expression Is an Independent Unfavorable Prognostic Factor in Esophageal Squamous Cell Carcinoma

  2007cited by this paper
• Association analysis of glutathione‐S‐transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M‐VAC chemotherapy

  2007cited by this paper
• Genetic polymorphisms and esophageal cancer risk

  2007cited by this paper
• Capecitabine: in advanced gastric or oesophagogastric cancer.

  2007cited by this paper
• Epidemiology and pathogenesis of esophageal cancer.

  2007cited by this paper
• Favorable Genetic Polymorphisms Predictive of Clinical Outcome of Chemoradiotherapy for Stage II/III Esophageal Squamous Cell Carcinoma in Japanese

  2007cited by this paper
• Overview of the changing paradigm in cancer treatment: oral chemotherapy.

  2007cited by this paper
• Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma.

  2007cited by this paper
• Chemoradiation in the management of esophageal cancer.

  2007cited by this paper
• Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.

  2007cited by this paper
• The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus

  2007cited by this paper
• Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.

  2007cited by this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cited by this paper
• Results of the 1999 2001 Japanese patterns of care study for patients receiving definitive radiation therapy without surgery for esophageal cancer.

  2007cited by this paper
• Circadian rhythms in the CNS and peripheral clock disorders: chronopharmacological findings on antitumor drugs.

  2007cited by this paper
• Early squamous cell carcinoma of the oesophagus: the Japanese viewpoint

  2007cited by this paper
• Combined modality chemoradiation in elderly oesophageal cancer patients

  2007cited by this paper
• A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.

  2007cited by this paper
• Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer.

  2007cited by this paper
• Are squamous and adenocarcinomas of the esophagus the same disease?

  2007cited by this paper
• Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.

  2007cited by this paper
• Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma.

  2007cited by this paper
• Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.

  2007cited by this paper
• Primary combined-modality therapy for esophageal cancer.

  2006cited by this paper
• Pharmacogenetics of cancer chemotherapy.

  2006cited by this paper
• Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

  2006cited by this paper
• VEGF receptor signalling ? in control of vascular function

  2006cited by this paper
• Expression of Genes Related to Activity of Oxaliplatin and 5-Fluorouracil in Endoscopic Biopsies of Primary Esophageal Cancer in Patients Receiving Oxaliplatin, 5-Flourouracil and Radiation: Characterization and Exploratory Analysis with Survival

  2006cited by this paper
• Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer

  2006cited by this paper
• A pharmacokinetic‐based test to prevent severe 5‐fluorouracil toxicity

  2006cited by this paper
• Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas

  2006cited by this paper
• Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

  2006cited by this paper
• Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma

  2006cited by this paper
• Squamous cell carcinoma-antigen messenger RNA level in peripheral blood predicts recurrence after resection in patients with esophageal squamous cell carcinoma.

  2006cited by this paper
• Local signals in stem cell-based bone marrow regeneration

  2006cited by this paper
• Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.

  2006cited by this paper
• An equilibrium partitioning model connecting gene expression and cis-motif content

  2006cited by this paper
• A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

  2006cited by this paper
• Elevated tumour interleukin-1b is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer

  2006cited by this paper
• Therapeutic Drug Monitoring for Dose Individualization of Cisplatin in Testicular Cancer Patients Based Upon Total Platinum Measurement in Plasma

  2006cited by this paper
• Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation.

  2006cited by this paper
• Biology of vascular endothelial growth factors

  2006cited by this paper
• Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients

  2006cited by this paper
• Predictive and prognostic molecular markers in outcome of esophageal cancer.

  2006cited by this paper
• Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma

  2006cited by this paper
• Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

  2006cited by this paper
• Local signals in stem cell-based bone marrow regeneration

  2006cited by this paper
• Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer

  2006cited by this paper
• Methylation in esophageal carcinogenesis.

  2006cited by this paper
• How may Anticancer Chemotherapy with Fluorouracil be Individualised?

  2006cited by this paper

• Exploring metabolic reprogramming in esophageal cancer: the role of key enzymes in glucose, amino acid, and nucleotide pathways and targeted therapies

  2025cites this paper
• RNA N4-acetylcytidine Modification in Gastrointestinal Cancer: Novel Functions, Mechanisms, and Therapeutic Implications.

  2025cites this paper
• Molecular subtyping and precision therapy for esophageal cancer

  2025cites this paper
• Recent advances in the potential role of RNA N4-acetylcytidine in cancer progression

  2024cites this paper
• NAT10-mediated ac4C tRNA modification promotes EGFR mRNA translation and gefitinib resistance in cancer.

  2023cites this paper
• STAT3β Enhances Sensitivity to Concurrent Chemoradiotherapy by Inducing Cellular Necroptosis in Esophageal Squamous Cell Carcinoma

  2021cites this paper
• DNA Repair Protein Rad51 Induces Tumor Growth and Metastasis in Esophageal Squamous Cell Carcinoma via a p38/Akt-Dependent Pathway

  2019cites this paper
• SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes

  2019cites this paper
• Cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma

  2018cites this paper
• cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma

  2018cites this paper
• cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma

  2018cites this paper
• cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma

  2018cites this paper
• Title Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil / cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

  2018cites this paper
• Competitive binding of (-)-epigallocatechin-3-gallate and 5-fluorouracil to human serum albumin: A fluorescence and circular dichroism study.

  2017cites this paper
• Dual cyclin‐dependent kinase 4/6 inhibition by PD‐0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells

  2017cites this paper
• A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma

  2017cites this paper
• Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil

  2016cites this paper
• The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways

  2016cites this paper
• Population Pharmacokinetic–Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats

  2016cites this paper
• Evaluation of Cytogenetic Alterations in Peripheral Blood Lymphocytes of Esophageal Cancer Patients Treated with Radiotherapy or Chemoradiotherapy using Cytokinesis-Blocked Micronucleus Assay.

  2016cites this paper
• Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE2

  2016cites this paper
• Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats

  2016cites this paper
• Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats.

  2015cites this paper
• Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China

  2015cites this paper
• Establishment of a Non-Invasive Semi-Quantitative Bioluminescent Imaging Method for Monitoring of an Orthotopic Esophageal Cancer Mouse Model

  2014cites this paper
• A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin

  2013cites this paper
• Preliminary evaluation of the interactions of Panax ginseng and Salvia miltiorrhiza Bunge with 5-fluorouracil on pharmacokinetics in rats and pharmacodynamics in human cells.

  2013cites this paper
• VEGF -634C/G Genotype is Predictive of Long-term Survival after Treatment with a Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma

  2012cites this paper
• THRB Genetic Polymorphisms Can Predict Severe Myelotoxicity after Definitive Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma

  2012cites this paper
• Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

  2011cites this paper
• Effects of Bolus Injection of 5-Fluorouracil on Steady-State Plasma Concentrations of 5-Fluorouracil in Japanese Patients with Advanced Colorectal Cancer

  2011cites this paper
• Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro.

  2011cites this paper
• TNFRSF 1 B A 1466 G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil / cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

  2010cites this paper
• Chronotherapy and the molecular clock: Clinical implications in oncology.

  2010cites this paper
• Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma

  2010cites this paper
• TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

  2010cites this paper
• Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

  2009cites this paper
• Can surgeon's hand be replaced with a smart surgical instrument in esophagectomy?

  2009cites this paper